Article Information
History
- October 1, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- J. O’Nions1,*,
- L. Muir2,
- J. Zheng1,
- C. Rees-Spear2,
- A. Rosa3,
- C. Earl3,
- P. Cherepanov3,
- R. Gupta1,4,
- A. Khwaja1,4,
- C. Jolly2 and
- L.E. McCoy2,*
- 1Department of Haematology, University College London NHS Foundation Trust, London, UK
- 2Division of Infection and Immunity, University College London, London, UK
- 3The Francis Crick Institute, London, UK
- 4UCL Cancer Institute London, Paul O’Gorman Building, London, UK
- ↵*Co-corresponding authors: Jenny O’Nions jenny.o'nions{at}nhs.net, Laura McCoy l.mccoy{at}ucl.ac.uk
Posted October 01, 2020.
SARS-CoV-2 antibody responses in patients with aggressive haematological malignancies
